Maia Biotechnology reports 88% disease control rate in Phase 2 lung cancer trial
MAIA•Maia Biotechnology reported an 88% disease control rate in its Phase 2 THIO-101 lung cancer trial. The company said its Phase 3 THIO-104 trial is progressing toward an interim survival analysis in 2027.
1. Updated trial results
Maia Biotechnology reported updated interim Phase 2 THIO-101 results showing disease control with ateganosine in previously treated advanced non-small cell lung cancer. The expansion results aligned with earlier findings in patients whose cancer resisted chemotherapy and immunotherapy.
2. Next trial milestones
The company said further expansion data may support an FDA accelerated approval filing; the therapy has Fast Track designation. Its pivotal Phase 3 THIO-104 trial is progressing toward an interim survival analysis in 2027.




